Evidence for acute neurotoxicity after chemotherapy

Annals of Neurology

Volumn 68, Issue 6, 2010, Pages 806-815

  Petzold, Axel ^a   Mondria, Tjeerd ^b   Kuhle, Jens ^c   Rocca, Maria A ^d   Cornelissen, Jan ^b   Te Boekhorst, Peter ^b   Lowenberg, Bob ^b   Giovannoni, Gavin ^e   Filippi, Massimo ^d   Kappos, Ludwig ^c   Hintzen, Rogier ^b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c UNIVERSITY HOSPITAL BASEL   (Switzerland)

^d SAN RAFFAELE HOSPITAL   (Italy)

^e QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; GRANULOCYTE COLONY STIMULATING FACTOR; MESNA; PLACEBO; PREDNISOLONE; THYMOCYTE ANTIBODY;

ADULT; ARTICLE; BRAIN ATROPHY; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; EXPANDED DISABILITY STATUS SCALE; FEMALE; HEMATOLOGIC MALIGNANCY; HUMAN; HUMAN CELL; MALE; MULTIPLE SCLEROSIS; NERVE DEGENERATION; NEUROFILAMENT; NEUROTOXICITY; NUCLEAR MAGNETIC RESONANCE IMAGING; PNEUMOCYSTOSIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; SERUM SICKNESS;

ACUTE DISEASE; ADULT; ANTI-INFECTIVE AGENTS; BONE MARROW TRANSPLANTATION; BRAIN; CASE-CONTROL STUDIES; DISABILITY EVALUATION; DRUG THERAPY; FEMALE; HEMATOLOGIC NEOPLASMS; HUMANS; LONGITUDINAL STUDIES; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; NEUROFILAMENT PROTEINS; NEUROTOXICITY SYNDROMES; PREDNISOLONE; SINGLE-BLIND METHOD; STATISTICS, NONPARAMETRIC; TIME FACTORS; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION;

EID: 78650923263     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.22169     Document Type: Article

References (59)

1. Samijn JP, te Boekhorst PA, Mondria T, et al. Intense T cell depletion followed by autologous bone marrow transplantation for severe multiple sclerosis. J Neurol Neurosurg Psychiatry 2006; 77: 46-50.
2. Chen JT, Collins DL, Atkins HL, et al. Brain atrophy after immunoablation and stem cell transplantation in multiple sclerosis. Neurology 2006; 66: 1935-1907.
3. Taillibert S, Voillery D, Bernard-Mart C,. Chemobrain: is systemic chemotherapy neurotoxic? Curr Opin Oncol 2007; 19: 623-627.
4. Soussain C, Ricard D, Fike JR, et al. CNS complications of radiotherapy and chemotherapy. Lancet 2009; 374: 1639-1651.
5. Petzold A,. Neurofilament phosphoforms: surrogate markers for axonal injury, degeneration & loss. J Neurol Sci 2005; 233: 183-198.
6. Teunissen CE, Dijkstra C, Polman C,. Biological markers in CSF and blood for axonal degeneration in multiple sclerosis. Lancet Neurol 2005; 4: 32-41.
7. Rocca MA, Mondria T, Valsasina P, et al. A three-year study of brain atrophy after autologous hematopoietic stem cell transplantation in rapidly evolving secondary progressive multiple sclerosis. AJNR Am J Neuroradiol 2007; 28: 1659-1961.
8. Kurtzke JF,. Rating neurological impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33: 1444-1452.
9. Trapp BD, Peterson J, Ransohoff RM, et al. Axonal transection in the lesions of multiple sclerosis. N Eng J Med 1998; 338: 278-285.
10. Polman CH, Dahlke F, Thompson AJ, et al. Interferon beta-1b in secondary progressive multiple sclerosis-outline of the clinical trial. Mult Scler 1995; 1 (suppl 1): S51-S54.
11. Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. European Study Group on interferon beta-1b in secondary progressive MS. Lancet 1998; 9139: 1491-1497.
12. Petzold A, Keir G, Green AJE, et al. A specific ELISA for measuring neurofilament heavy chain phosphoforms. J Immunol Methods 2003; 278: 179-190.
13. Lycke JN, Karlsson JE, Andersen O, Rosengren LE,. Neurofilament protein in cerebrospinal fluid: a potential marker of activity in multiple sclerosis. J Neurol Neurosurg Psychiatry 1998; 64: 402-404.
14. Altmann DR, Jasperse B, Barkhof F, et al. Sample sizes for brain atrophy outcomes in trials for secondary progressive multiple sclerosis. Neurology 2009; 72: 595-601.
15. Jager HR, Williams EJ, Savage DG, et al. Assessment of brain changes with registered MR before and after bone marrow transplantation for chronic myeloid leukemia. AJNR Am J Neuroradiol 1996; 17: 1275-1282.
16. Blanco Y, Saiz A, Carreras E, Graus F,. Autologous haematopoietic-stem- cell transplantation for multiple sclerosis. Lancet Neurol 2005; 4: 54-63.
17. Mancardi GL, Saccardi R, Filippi M, et al and Italian GITMO-NEURO Intergroup on Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis. Autologous hematopoietic stem cell transplantation suppresses Gd-enhanced MRI activity in MS. Neurology 2001; 57: 62-68.
18. Inglese M, Mancardi GL, Pagani E, et al. Brain tissue loss occurs after suppression of enhancement in patients with multiple sclerosis treated with autologous haematopoietic stem cell transplantation. J Neurol Neurosurg Psychiatry 2004; 75: 643-644.
19. Inglese M, Benedetti B, Filippi M,. The relation between MRI measures of inflammation and neurodegeneration in multiple sclerosis. J Neurol Sci 2005; 233: 15-19.
20. Miller DH, Barkhof F, Frank JA, et al. Measurement of atrophy in multiple sclerosis: pathological basis, methodological aspects and clinical relevance. Brain 2002; 125: 1676-1695.
21. Prassopoulos P, Cavouras D, Evlogias N, Golfinopoulos S,. Brain atrophy in children undergoing systemic chemotherapy for extracranial solid tumors. Med Pediatr Oncol 1997; 28: 228-233.
22. Prassopoulos P, Cavouras D, Golfinopoulos S, et al. Quantitative assessment of cerebral atrophy during and after treatment in children with acute lymphoblastic leukemia. Invest Radiol 1996; 31: 749-754.
23. Brown MS, Simon JH, Stemmer SM, et al. MR and proton spectroscopy of white matter disease induced by high-dose chemotherapy with bone marrow transplant in advanced breast carcinoma. AJNR Am J Neuroradiol 1995; 16: 2013-2020.
24. Tannock IF, Ahles TA, Ganz PA, Van Dam FS,. Cognitive impairment associated with chemotherapy for cancer: report of a workshop. J Clin Oncol 2004; 22: 2233-2239.
25. McAllister TW, Ahles TA, Saykin AJ, et al. Cognitive effects of cytotoxic cancer chemotherapy: predisposing risk factors and potential treatments. Curr Psychiatry Rep 2004; 6: 364-371.
26. Matsuda T, Takayama T, Tashiro M, et al. Mild cognitive impairment after adjuvant chemotherapy in breast cancer patients-evaluation of appropriate research design and methodology to measure symptoms. Breast Cancer 2005; 12: 279-287.
27. Kayl AE, Wefel JS, Meyers CA,. Chemotherapy and cognition: effects, potential mechanisms, and management. Am J Ther 2006; 13: 362-369.
28. Shah AJ, Epport K, Azen C, et al. Progressive declines in neurocognitive function among survivors of hematopoietic stem cell transplantation for pediatric hematologic malignancies. J Pediatr Hematol Oncol 2008; 30: 411-418.
29. Harder H, Van Gool AR, Duivenvoorden HJ, et al. Case-referent comparison of cognitive functions in patients receiving haematopoietic stem-cell transplantation for haematological malignancies: two-year follow-up results. Eur J Cancer 2007; 43: 2052-1059.
30. Falleti MG, Sanfilippo A, Maruff P, et al. The nature and severity of cognitive impairment associated with adjuvant chemotherapy in women with breast cancer: a meta-analysis of the current literature. Brain Cogn 2005; 59: 60-70.
31. Petzold A, Altintas A, Andreoni L, et al. Neurofilament ELISA validation. J Immunol Methods 2010; 352: 23-31.
32. Thambisetty M, Lovestone S,. Blood-based biomarkers of Alzheimer's disease: challenging but feasible. Biomark Med 2010; 4: 65-79.
33. Petzold A, Gveric D, Groves M, et al. Phosphorylation and compactness of neurofilaments in multiple sclerosis: indicators of axonal pathology. Exp Neurol 2008; 213: 326-335.
34. Anderson KJ, Scheff SW, Miller KM, et al. The phosphorylated axonal form of the neurofilament subunit NF-H (pNF-H) as a blood biomarker of traumatic brain injury. J Neurotrauma 2008; 25: 1079-1085.
35. Marszalek JR, Williamson TL, Lee MK, et al. Neurofilament subunit NF-H modulates axonal diameter by selectively slowing neurofilament transport. J Cell Biol 1996; 135: 711-724.
36. Petzold A, Hinds N, Murray NM, et al. CSF neurofilament levels: a potential prognostic marker in Guillain-Barre syndrome. Neurology 2006; 67: 1071-1073.
37. Petzold A, Brettschneider J, Jin K, et al. CSF protein biomarkers for proximal axonal damage improve prognostic accuracy in the acute phase of Guillain-Barré syndrome. Muscle Nerve 2009; 40: 42-49.
38. Petzold A, Groves M, Leis AA, et al. Neuronal and glial cerebrospinal fluid protein biomarkers are elevated after West Nile virus infection. Muscle Nerve 2010; 41: 42-49.
39. Petzold A, Keir G, Warren J, et al. A systematic review and meta-analysis of CSF neurofilament protein levels as biomarkers in dementia. Neurodegener Dis 2007; 4: 185-194.
40. Blennow K, de Leon MJ, Zetterberg H,. Alzheimer's disease. Lancet 2006; 368: 387-403.
41. von Wedel-Parlow M, Wölte P, Galla HJ,. Regulation of major efflux transporters under inflammatory conditions at the blood-brain barrier in vitro. J Neurochem 2009; 111: 111-118.
42. Cotte S, von Ahsen N, Kruse N, et al. ABC-transporter gene-polymorphisms are potential pharmacogenetic markers for mitoxantrone response in multiple sclerosis. Brain 2009; 132 (pt 9): 2517-2530.
43. Dietrich J, Han R, Yang Y, et al. CNS progenitor cells and oligodendrocytes are targets of chemotherapeutic agents in vitro and in vivo. J Biol 2006; 5: 22.
44. Fassas A, Mancardi GL,. Autologous hemopoietic stem cell transplantation for multiple sclerosis: is it worthwile? Autoimmunity 2008; 41: 601-610.
45. Stangel M,. Multiple sclerosis: hematopoietic stem cell transplantation: hope and hype. Nat Rev Neurol 2009; 5: 300-302.
46. Freedman MS,. Bone marrow transplantation: does it stop MS progression? J Neurol Sci 2007; 259: 85-89.
47. Noseworthy JH,. Multiple sclerosis clinical trials: old and new challenges. Sem Neurol 1998; 18: 377-388.
48. van Bekkum DW,. Effectiveness and risks of total body irradiation for conditioning in the treatment of autoimmune disease with autologous bone marrow transplantation. Rheumatology (Oxford) 1999; 38: 757-761.
49. Murphy A, Breen KC, Long A, et al. Neurofilament expression in human T lymphocytes. Immunology 1993; 79: 167-170.
50. Shaw G, Yang C, Ellis R, et al. Hyperphosphorylated neurofilament NF-H is a serum biomarker for axonal injury. Biochem Biophys Res Commun 2005; 336: 1268-1277.
51. Abdo WF, van de Warrenburg BP, Munneke M, et al. CSF analysis differentiates multiple-system atrophy from idiopathic late-onset cerebellar ataxia. Neurology 2006; 67: 474-479.
52. Teunissen CE, Iacobaeus E, Khademi M, et al. Combination of CSF n-acetylaspartate and neurofilaments in multiple sclerosis. Neurology 2009; 72: 1322-1329.
53. Kuhle J, Regeniter A, Leppert D, et al. A highly sensitive electrochemiluminescence immunoassay for the neurofilament heavy chain protein. J Neuroimmunol 2010; 220: 114-119.
54. Petzold A, Shaw G,. Comparison of two ELISA methods for measuring levels of the phosphorylated neurofilament heavy chain. J Immunol Methods 2007; 319: 34-40.
55. Butler RW, Mulhern RK,. Neurocognitive interventions for children and adolescents surviving cancer. J Pediatr Psychol 2005; 30: 65-78.
56. Moore BD III,. Neurocognitive outcomes in survivors of childhood cancer. J Pediatr Psychol 2005; 30: 51-63.
57. Kanard A, Frytak S, Jatoi A,. Cognitive dysfunction in patients with small-cell lung cancer: incidence, causes, and suggestions on management. J Support Oncol 2004; 2: 127-132; discussion 133-135, 138-140.
58. Minisini A, Atalay G, Bottomley A, et al. What is the effect of systemic anticancer treatment on cognitive function? Lancet Oncol 2004; 5: 273-282.
59. Petzold A, de Boer JF, Schippling S, et al. Optical coherence tomography in multiple sclerosis: a systematic review and meta-analysis. The Lancet Neurology 2010; 9: 921-932.